Recently, FDA approved the use of the oral PI3K inhibitor alpelisib (Piqray) in the treatment of HR+ metastatic BC patients with mutated PIK3CA [189], collectively providing a hint at the potential use of TQ in combination with alpelisib. Here, PIK3CA is linked to breast cancer.